Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD81 | P60033 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2560475 | 1.00 | CD81 (0.35) | CD81MEN1KMT2APPARGCHRM2 | |
| SCHEMBL637536 | 0.89 | CD81 (0.33) | CD81MEN1KMT2APPARG | |
| SCHEMBL3284748 | 0.87 | EP300 (0.35) | CD81MEN1KMT2A | |
| SCHEMBL4417777 | 0.86 | CD81 (0.37) | CD81PPARG | |
| SCHEMBL3210711 | 0.82 | CD81 (0.34) | CD81PPARG | |
| SCHEMBL28547823 | 0.82 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL28808739 | 0.79 | MAPT (0.33) | MEN1KMT2A | |
| SCHEMBL3278759 | 0.79 | CD81 (0.30) | CD81 | |
| SCHEMBL28934194 | 0.78 | CHRM2 (0.33) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2634193 | 0.77 | CA12 (0.35) | CD81PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4455168-B1 | VISIBLE LIGHT CURABLE COMPOSITION AND VISIBLE LIGHT CURABLE COMPOSITION POLYMERIZATION METHOD | CHT TURKEY KIMYA SANAYI VE TICARET A S (TR) | 2025-12-24 | — | — | EP | claimed |
| EP-3872573-B1 | TONER ADDITIVE FORMULATION WITH CROSS-LINKED ORGANIC POLYMERIC ADDITIVE | XEROX CORP (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3395876-B1 | NOVEL NANOPARTICLES | COVESTRO NETHERLANDS BV (NL) | 2024-07-31 | — | — | EP | claimed |
| EP-3368593-B1 | IMPROVED BINDER COMPOSITIONS AND USES THEREOF | KNAUF INSULATION SPRL (BE) | 2023-12-06 | — | — | EP | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-3571293-B1 | A THERMORESPONSIVE MICROCARRIER SYSTEM AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2023-04-12 | — | — | EP | claimed |
| EP-3720890-B1 | USE OF ANTIMICROBIAL ETHYLENE COPOLYMERS FOR PACKAGING APPLICATIONS | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2022-12-28 | — | — | EP | claimed |
| US-20220226510-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-07-21 | — | — | US | claimed |
| EP-3368207-B1 | ENCAPSULATION | ENCAPSYS LLC (US) | 2021-12-01 | — | — | EP | claimed |
| EP-2951216-B1 | ANTI-MICROBIAL POLYMER | FACHHOCHSCHULE MUENSTER (DE) | 2018-07-18 | — | — | EP | claimed |
| US-8106113-B2 | Ink composition, image forming method and printed article | FUJIFILM CORPORATION (JP) | 2012-01-31 | — | — | US | claimed |
| EP-2382315-A1 | NUCLEIC ACID PURIFICATION METHOD | Qiagen GmbH (DE) | 2011-11-02 | — | — | EP | claimed |
| US-7820753-B2 | Block copolymers | BIOCOMPATIBLES UK LIMITED (GB) | 2010-10-26 | — | — | US | claimed |
| WO-2010072834-A1 | NUCLEIC ACID PURIFICATION METHOD | QIAGEN GMBH (DE) | 2010-07-01 | — | — | WO | claimed |
| EP-1842601-B1 | Method for forming functional layers | CIBA HOLDING INC (CH) | 2009-07-22 | — | — | EP | claimed |
| US-20090103045-A1 | SILICONE HYDROGELS WITH AMINO SURFACE GROUPS | SALIX PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | claimed |
| US-20070244248-A1 | Copolymers useful as demulsifiers and clarifiers | BAKER HUGHES INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| EP-1842601-A1 | Method for forming functional layers | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-10-10 | — | — | EP | claimed |
| US-20070113353-A1 | Polymeric Surface Treatment Compositions | THE CLOROX COMPANY | 2007-05-24 | — | — | US | claimed |
| EP-0420687-B1 | Discoloration-resistant spandex | DU PONT (US) | 1996-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226510-A1 | STIMULI-RESPONSIVE NANOPARTICLES FOR BIOMEDICAL APPLICATIONS | HSPA9, LRBA, AHSA1 | CD81 2045/4885MEN1 1698/4885KMT2A 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.